Barriers in precision medicine implementation among Advanced Nonsquamous Cell Lung Cancer-patients: A Real-World Evidence Scenario

Precision oncology has a prominent role in nonsquamous non-small cell lung cancer (nsNSCLC) treatment progress; however, its access in a real-world scenario might be limited. To investigate the time spent in nsNSCLC molecular profile evaluation and its influence on clinical decisions. nsNSCLC patien...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of market access & health policy 2022-12, Vol.10 (1), p.2077905-2077905
Main Authors:	Duarte, Flavia A., Ferreira, Carlos Gil, Dienstmann, Rodrigo, Ferrari, Bruno L., Costa E Silva, Matheus, Nazareth A. Junior, Pedro, Guilherme de O. Salles, Paulo, Henrique C. Diniz, Paulo
Format:	Article
Language:	eng
Subjects:	Biomarkers drug access Lung cancer Medical treatment non-small cell lung cancer Patients Practical Applications Precision medicine Time
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Precision oncology has a prominent role in nonsquamous non-small cell lung cancer (nsNSCLC) treatment progress; however, its access in a real-world scenario might be limited. To investigate the time spent in nsNSCLC molecular profile evaluation and its influence on clinical decisions. nsNSCLC patients who underwent molecular testing in a private referral Brazilian center between November 2015 and February 2020 were identified. The interval from nsNSCLC diagnosis to the characterization of the molecular profile was determined. Other outcomes, focusing on the biomarker tissue journey, were also assessed. In this cohort (n = 78), the median time between the advanced nsNSCLC diagnosis and biomarker characterization was 40.5 days (range, 29.5-68.5). The median interval between the diagnosis and the test request was longer than the interval between the request and the results (respectively 29.0 versus 12.0 days; p
ISSN:	2001-6689 2001-6689